



Reference Diagnostic Division
Oxford Immunotec, Inc. d/b/a IMUGEN
315 Norwood Park South, Norwood MA 02062

Laboratory Results

Submitter:

WOODSON C MERRELL MD
SUITE 1B
44 EAST 67TH STREET
NEW YORK, NY 10065

Patient:

Name: JEFFREY EPSTEIN
Address: 9 EAST 71ST STREET
NEW YORK, NY 10021

D.O.B.: 1/20/1953

**Ordering
Provider:**

WOODSON C MERRELL MD

**Submitter
Record #:**

Account #: MERW

IMUGEN
Patient #: 2018013061

Borrelia miyamotoi Serology

PLASMA #: 13061
PLASMA Collection Date: 09/14/2018
PLASMA Receipt Date: 09/17/2018

Test Method: Indirect EIA (Recombinant Antigen)*

Test Date: 09/18/2018

Antigen	Antibody Isotype	Result
GlpQ*	IgM	<1
GlpQ*	IgG	4.4

Reportable Range: IgM ELISA: <1 to the value calculated for the highest result on the standard curve.
Reportable Range: IgG ELISA: <1 to the value calculated for the highest result on the standard curve.
Normal Range is negative: ratio of <1 for IgM and <1 for IgG.

Comments: IgG is positive. IgM is negative.

Interpretation: These findings are compatible with either an infection with *B. miyamotoi* at an undetermined time or cross-reacting IgG antibody.

Note 1: Results should be evaluated in conjunction with clinical presentation and other medical and diagnostic findings.
Note 2: Although numeric values are provided on the test report, these values are only relevant when compared to another sample from the same patient on the same test run. To determine whether a patient has significant changes in antibody response, a second sample (e.g., convalescent sample) may be submitted. The laboratory will analyze the prior sample alongside the newly submitted sample on the same test run.
Note 3: A negative result does not exclude the possibility of infection with *B. miyamotoi*. Antibodies may not yet be present at the time of blood sample collection or may not yet be detectable. If the acute specimen is negative (i.e. antibodies undetectable) and the clinical history strongly suggests infection, collection of a convalescent specimen 3-4 weeks later is recommended. Treatment should never be delayed pending the receipt of laboratory test results, or be withheld on the basis of an initial negative laboratory result.
Note 4: A positive result is not definitive evidence of infection with *B. miyamotoi*. Infection with *Borrelia burgdorferi* or *Borrelia microti* may cause a positive response.
Note 5: This test was developed and its performance characteristics determined by IMUGEN. It has not been cleared or approved by the FDA. This laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

The IMUGEN logo is a registered trademark of Oxford Immunotec, Ltd.
© 2017 Oxford Immunotec.

Report Date: 09/19/2018

ARM

Mihae Platt M.D., Ph.D. Director
CLIA number 22D0650196